<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03510481</url>
  </required_header>
  <id_info>
    <org_study_id>999918084</org_study_id>
    <secondary_id>18-I-N084</secondary_id>
    <nct_id>NCT03510481</nct_id>
  </id_info>
  <brief_title>Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali</brief_title>
  <official_title>Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanaria Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malaria Research and Training Center, Bamako, Mali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      The disease malaria affects many people in Mali and other parts of Africa and the world. It&#xD;
      is caused by germs spread by mosquito bites. Malaria may be mild. But it can also be serious&#xD;
      or lead to death if it is not treated promptly. Researchers want to find a safe vaccine that&#xD;
      prevents malaria.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To study how safe and tolerable the malaria vaccine called PfSPZ Vaccine is for healthy&#xD;
      adults.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Healthy adults:&#xD;
&#xD;
        -  ages 18-35 in Ouelessebougou, Mali&#xD;
&#xD;
        -  not infected with HIV, hepatitis B, or hepatitis C&#xD;
&#xD;
        -  for females, not pregnant or breastfeeding and must use reliable birth control during&#xD;
           the study&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with questions about malaria and will undergo blood, urine, and&#xD;
      heart tests.&#xD;
&#xD;
      Participants will be randomly assigned to 1 of 4 groups. They will get injections of either&#xD;
      the PfSPZ Vaccine or a salt-water placebo. They will not know which one they get.&#xD;
&#xD;
      Vaccinations will occur leading into the malaria transmission each year with 3 injections&#xD;
      leading into Year 1 (malaria transmission season in 2018) and 1 injection prior to Year 2&#xD;
      (malaria transmission season 2019).&#xD;
&#xD;
      One vaccine group and one placebo group will get an injection 3 times over 4 weeks with an&#xD;
      additional vaccination ~10 months later.&#xD;
&#xD;
      The other two groups (vaccine group and placebo) will get an injection 3 times over 16 weeks&#xD;
      with an additional vaccination ~10 months later.&#xD;
&#xD;
      All participants will be treated with an antimalarial medication prior to the third injection&#xD;
      and prior to fourth injection.&#xD;
&#xD;
      They will be followed for approximately 6 months after third and fourth injection.&#xD;
&#xD;
      At vaccine visits, female participants will have a pregnancy test before injection. All&#xD;
      participants will have an arm cleaned and the vaccine injected in a vein. They will be&#xD;
      watched for 30 minutes.&#xD;
&#xD;
      At non-vaccine visits, participants will have a physical exam and be asked how they are&#xD;
      feeling. They will usually have blood tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that humans can be protected against malaria by repeated immunization with&#xD;
      radiation-attenuated sporozoites. Sanaria, Inc. has developed a process for manufacturing, in&#xD;
      compliance with current Good Manufacturing Practices (cGMPs) aseptic, purified, radiation-&#xD;
      attenuated cryopreserved sporozoites from a well-characterized isolate of Plasmodium&#xD;
      falciparum (Pf). This product, which is called PfSPZ Vaccine, can be administered by needle&#xD;
      and syringe.&#xD;
&#xD;
      A collaboration among the Malaria Research and Training Center (MRTC, Mali), the Laboratory&#xD;
      of Malaria Immunology and Vaccinology (LMIV) National Institute of Allergy and Infectious&#xD;
      Diseases (NIAID), and Sanaria, Inc. has shown that sterile protection against naturally&#xD;
      occurring malaria infection can be achieved. In this study, five doses of 2.7 x 10^5 PfSPZ&#xD;
      during the dry season resulted in protective efficacies of about 48% by time to first&#xD;
      positive blood smears (BS) and about 29% by proportion of participants with at least one&#xD;
      positive BS during a full malaria transmission season (20 weeks), higher than those reported&#xD;
      for other malaria vaccine candidates.&#xD;
&#xD;
      A follow up study in 2015 (ClinicalTrials.gov Identifier: NCT02627456) that reduced the&#xD;
      number of vaccinations (from 5 to 3) while increasing the dose of sporozoites at each&#xD;
      vaccination (2.7 x10^5 to 1.8x10^6 PfSPZ Vaccine) was conducted. Preliminary results show&#xD;
      that 42 of 55 (77.8%) participants from the placebo group and 32 of 54 participants (58.1%)&#xD;
      from the vaccine group developed Pf infection. Per protocol, the vaccine efficacy (VE) was&#xD;
      51% (p=0.004, 95% CI 20-70) by time-to-infection analysis (intention to treat (ITT) 39%,&#xD;
      p=0.033) and 24% (p=0.031, 95% CI 2-41) by proportional analysis (ITT 22%, p= 0.041), similar&#xD;
      to the previous study.&#xD;
&#xD;
      Studies are ongoing to establish a vaccination regimen, optimum dose and schedule, that will&#xD;
      lead to improved sterile protection in endemic regions. Preliminary results from more recent&#xD;
      studies in malaria-na√Øve and malaria-experienced participants have shown that 9.0x10^5 PfSPZ&#xD;
      Vaccine dose per vaccination (lower than 1.8 x10^6 used in studies above) in a three-dose&#xD;
      regimen may be an optimal dose for immunization. In addition, there is emerging evidence that&#xD;
      a condensed, more practical regimen may also lead to development of sterile immunity. This&#xD;
      proposed study is therefore designed to assess safety, immunogenicity and protective efficacy&#xD;
      of two separate three-dose vaccination regimens during natural transmission season.&#xD;
&#xD;
      Participants in the main phase were randomized into arms receiving either PfSPZ Vaccine or&#xD;
      normal saline injections. Each group received three doses of the respective injection during&#xD;
      Year 1. After completion of the follow up in the main phase, all participants that are still&#xD;
      enrolled in the study will be offered continued participation to receive a booster dose of&#xD;
      the vaccine (dose # 4) with 9.0x10^5 PfSPZ or normal saline (depending on the group they were&#xD;
      originally randomized to) at approximately 10 months post #3 vaccination. The booster dose is&#xD;
      timed prior to ensuing malaria transmission season. Participants will be followed, similarly&#xD;
      to the follow up during the main phase, for safety and vaccine efficacy for approximately 6&#xD;
      months during this second transmission season.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2018</start_date>
  <completion_date type="Actual">February 13, 2020</completion_date>
  <primary_completion_date type="Actual">November 23, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Local and Systemic Adverse Events in Year One</measure>
    <time_frame>Within 7 days after each vaccination in year one</time_frame>
    <description>Incidence of local and systemic adverse events (AEs) graded by severity occurring within 7 days after each vaccine administration in year one</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Local and Systemic Adverse Events in Year Two</measure>
    <time_frame>Within 7 days after each vaccination in year two</time_frame>
    <description>Incidence of local and systemic adverse events (AEs) graded by severity occurring within 7 days after vaccine administration during year two (booster dose)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">478</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Experimental arm 1: Dosing interval 0, 8, 16, and 54 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm 2: Dosing interval 0, 1, 4, and 42 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator 3a: Dosing interval 0, 8, 16, and 54 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator 3b: Dosing interval 0, 1, 4, and 42 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PfSPZ Vaccine</intervention_name>
    <description>PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.</description>
    <arm_group_label>Experimental arm 1: Dosing interval 0, 8, 16, and 54 weeks</arm_group_label>
    <arm_group_label>Experimental arm 2: Dosing interval 0, 1, 4, and 42 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.</description>
    <arm_group_label>Placebo comparator 3a: Dosing interval 0, 8, 16, and 54 weeks</arm_group_label>
    <arm_group_label>Placebo comparator 3b: Dosing interval 0, 1, 4, and 42 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artemether 20mg/lumefantrine 120mg (AL)</intervention_name>
    <description>Licensed antimalarial in the US and Mali for use for uncomplicated malaria.</description>
    <arm_group_label>Experimental arm 1: Dosing interval 0, 8, 16, and 54 weeks</arm_group_label>
    <arm_group_label>Experimental arm 2: Dosing interval 0, 1, 4, and 42 weeks</arm_group_label>
    <arm_group_label>Placebo comparator 3a: Dosing interval 0, 8, 16, and 54 weeks</arm_group_label>
    <arm_group_label>Placebo comparator 3b: Dosing interval 0, 1, 4, and 42 weeks</arm_group_label>
    <other_name>Coartem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Age greater than or equal to 18 and less than or equal to 35 years&#xD;
&#xD;
               2. Able to provide proof of identity to the satisfaction of the study clinician&#xD;
                  completing the enrollment process&#xD;
&#xD;
               3. In good general health and without clinically significant medical history&#xD;
&#xD;
               4. Willing to have blood samples stored for future research&#xD;
&#xD;
               5. Available for the duration of the study&#xD;
&#xD;
               6. Females of childbearing potential must be willing to use reliable contraception&#xD;
                  (as defined below) from 21 days prior to Study Day 1 to 28 days after last&#xD;
                  vaccination.&#xD;
&#xD;
                    -  Reliable methods of birth control include:&#xD;
&#xD;
                         -  one of the following: confirmed pharmacologic contraceptives&#xD;
                            (parenteral) delivery; intrauterine or implantable device. OR&#xD;
&#xD;
                         -  two of the following: a documented oral or transdermal or vaginal ring&#xD;
                            contraceptives; PLUS condoms with spermicide or diaphragm with&#xD;
                            spermicide.&#xD;
&#xD;
                    -  Note, Coartem (artemether specifically) may reduce the effectiveness of&#xD;
                       systemic hormonal contraceptives, therefore additional barrier methods such&#xD;
                       as condoms must also be used during the 3 days of Coartem dosing.&#xD;
&#xD;
                    -  Women who are not able to get pregnant will also be required to report date&#xD;
                       of last menstrual period, history of surgical sterility (i.e. tubal&#xD;
                       ligation, hysterectomy) or premature ovarian insufficiency (POI), and will&#xD;
                       have urine or serum pregnancy test performed per protocol.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Pregnancy, as determined by a positive urine or serum human chorionic gonadotropin&#xD;
             (beta-hCG) test (if female). NOTE: Pregnancy is also a criterion for discontinuation&#xD;
             of any further dosing or non-safety related interventions for that subject.&#xD;
&#xD;
          2. Currently breast-feeding (if female)&#xD;
&#xD;
          3. Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator&#xD;
             affects the ability of the participant to understand and comply with the study&#xD;
             protocol&#xD;
&#xD;
          4. Hemoglobin (Hb), WBC, absolute neutrophils, and platelets outside the local&#xD;
             laboratory- defined limits of normal (subjects may be included at the investigator s&#xD;
             discretion for not clinically significant values)&#xD;
&#xD;
          5. Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined&#xD;
             upper limit of normal (subjects may be included at the investigator s discretion for&#xD;
             not clinically significant values)&#xD;
&#xD;
          6. Infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or&#xD;
             hepatitis B (HBV)&#xD;
&#xD;
          7. Known or documented sickle cell disease by history (Note: known sickle cell trait is&#xD;
             NOT exclusionary)&#xD;
&#xD;
          8. Clinically significant abnormal electrocardiogram (ECG) such as abnormal QTc.&#xD;
&#xD;
          9. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine,&#xD;
             rheumatologic, autoimmune, hematological, oncologic, or renal disease by history,&#xD;
             physical examination, and/or laboratory studies including urinalysis&#xD;
&#xD;
         10. History of receiving any investigational product within the past 30 days&#xD;
&#xD;
         11. Participation or planned participation in a clinical trial with an investigational&#xD;
             product prior to completion of the follow-up visit 28 days following last vaccination&#xD;
             OR planned participation in an investigational vaccine study until the last required&#xD;
             protocol visit&#xD;
&#xD;
         12. Medical, occupational, or family problems as a result of alcohol or illicit drug use&#xD;
             during the past 12 months&#xD;
&#xD;
         13. History of a severe allergic reaction(Grade 3 or higher or per PI discretion) or&#xD;
             anaphylaxis&#xD;
&#xD;
         14. Severe asthma (defined as asthma that is unstable or required emergent care, urgent&#xD;
             care, hospitalization, or intubation during the past two years, or that has required&#xD;
             the use of oral or parenteral corticosteroids at any time during the past two years)&#xD;
&#xD;
         15. Pre-existing autoimmune or antibody-mediated diseases including but not limited to:&#xD;
             systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's&#xD;
             syndrome, or autoimmune thrombocytopenia&#xD;
&#xD;
         16. Known immunodeficiency syndrome&#xD;
&#xD;
         17. Known asplenia or functional asplenia&#xD;
&#xD;
         18. Use of:&#xD;
&#xD;
               -  Chronic (greater than or equal to 14 days) oral or IV corticosteroids (excluding&#xD;
                  topical or nasal) at immunosuppressive doses (i.e., prednisone &gt;10 mg/day) or&#xD;
                  immunosuppressive drugs within 30 days of vaccination&#xD;
&#xD;
               -  Use of antimalarials or systemic antibiotics with known antimalarial activity&#xD;
                  within 5 drug half-lives prior to the first vaccine (such as artemether,&#xD;
                  artemether-lumefantrine, sulfadoxine-pyrimethamine,&#xD;
                  trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin,&#xD;
                  erythromycin, fluoroquinolones or azithromycin)&#xD;
&#xD;
         19. Receipt of a live vaccine within the past four weeks or a killed vaccine within the&#xD;
             past two weeks prior to Vaccination #1 and every subsequent vaccination day&#xD;
&#xD;
         20. Receipt of immunoglobulins and/or blood products within the past six months&#xD;
&#xD;
         21. Previous receipt of an investigational malaria vaccine in the last five years&#xD;
&#xD;
         22. Known allergies or other contraindications against Coartem&#xD;
&#xD;
         23. Other condition(s) that, in the opinion of the investigator, would jeopardize the&#xD;
             safety or rights of a participant participating in the trial, interfere with the&#xD;
             evaluation of the study objectives, or would render the subject unable to comply with&#xD;
             the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick E Duffy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malaria Research and Training Center</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mali</country>
  </location_countries>
  <reference>
    <citation>Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, Kamate B, Samake Y, Guindo MA, Dolo A, Niangaly A, Niar√© K, Zeguime A, Sissoko K, Diallo H, Thera I, Ding K, Fay MP, O'Connell EM, Nutman TB, Wong-Madden S, Murshedkar T, Ruben AJ, Li M, Abebe Y, Manoj A, Gunasekera A, Chakravarty S, Sim BKL, Billingsley PF, James ER, Walther M, Richie TL, Hoffman SL, Doumbo O, Duffy PE. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017 May;17(5):498-509. doi: 10.1016/S1473-3099(17)30104-4. Epub 2017 Feb 16.</citation>
    <PMID>28216244</PMID>
  </reference>
  <reference>
    <citation>Jongo SA, Church LWP, Mtoro AT, Schindler T, Chakravarty S, Ruben AJ, Swanson PA, Kassim KR, Mpina M, Tumbo AM, Milando FA, Qassim M, Juma OA, Bakari BM, Simon B, James ER, Abebe Y, Kc N, Saverino E, Fink M, Cosi G, Gondwe L, Studer F, Styers D, Seder RA, Schindler T, Billingsley PF, Daubenberger C, Sim BKL, Tanner M, Richie TL, Abdulla S, Hoffman SL. Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults. Clin Infect Dis. 2020 Dec 31;71(11):2849-2857. doi: 10.1093/cid/ciz1152.</citation>
    <PMID>31782768</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <results_first_submitted>May 7, 2021</results_first_submitted>
  <results_first_submitted_qc>August 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2021</results_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PfSPZ Vaccine</keyword>
  <keyword>Malaria</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03510481/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>478 subjects signed consent. 251 subjects were screen failures. 17 subjects were enrolled but not vaccinated. 210 subjects started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental Arm 1: Dosing Interval 0, 8, 16, and 54 Weeks</title>
          <description>Participants received 3 doses of PfSPZ Vaccine (9 x10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
        <group group_id="P2">
          <title>Experimental Arm 2: Dosing Interval 0, 1, 4, and 42 Weeks</title>
          <description>Participants received 3 doses of PfSPZ Vaccine (9 x10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
        <group group_id="P3">
          <title>Placebo Comparator 3a: Dosing Interval 0, 8, 16, and 54 Weeks</title>
          <description>Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Comparator 3b: Dosing Interval 0, 1, 4, and 42 Weeks</title>
          <description>Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 2 - Booster Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46">10 participants who completed Period 1 did not re-consent for Period 2.</participants>
                <participants group_id="P2" count="52">9 participants who completed Period 1 did not re-consent for Period 2.</participants>
                <participants group_id="P3" count="25">9 participants who completed Period 1 did not re-consent for Period 2.</participants>
                <participants group_id="P4" count="19">12 participants who completed Period 1 did not re-consent for Period 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Arm 1: Dosing Interval 0, 8, 16, and 54 Weeks</title>
          <description>Participants received 3 doses of PfSPZ Vaccine (9 x10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
        <group group_id="B2">
          <title>Experimental Arm 2: Dosing Interval 0, 1, 4, and 42 Weeks</title>
          <description>Participants received 3 doses of PfSPZ Vaccine (9 x10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
        <group group_id="B3">
          <title>Placebo Comparator 3a: Dosing Interval 0, 8, 16, and 54 Weeks</title>
          <description>Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Comparator 3b: Dosing Interval 0, 1, 4, and 42 Weeks</title>
          <description>Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="35"/>
            <count group_id="B5" value="210"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Bambara</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bozo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malinke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peuhl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sarakole</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Songrai</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mali</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Local and Systemic Adverse Events in Year One</title>
        <description>Incidence of local and systemic adverse events (AEs) graded by severity occurring within 7 days after each vaccine administration in year one</description>
        <time_frame>Within 7 days after each vaccination in year one</time_frame>
        <population>The analyses included only subjects who received at least one vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm 1: Dosing Interval 0, 8, 16, and 54 Weeks</title>
            <description>Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
          </group>
          <group group_id="O2">
            <title>Experimental Arm 2: Dosing Interval 0, 1, 4, and 42 Weeks</title>
            <description>Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Comparator 3a: Dosing Interval 0, 8, 16, and 54 Weeks</title>
            <description>Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Comparator 3b: Dosing Interval 0, 1, 4, and 42 Weeks</title>
            <description>Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local and Systemic Adverse Events in Year One</title>
          <description>Incidence of local and systemic adverse events (AEs) graded by severity occurring within 7 days after each vaccine administration in year one</description>
          <population>The analyses included only subjects who received at least one vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Local and Systemic Adverse Events in Year Two</title>
        <description>Incidence of local and systemic adverse events (AEs) graded by severity occurring within 7 days after vaccine administration during year two (booster dose)</description>
        <time_frame>Within 7 days after each vaccination in year two</time_frame>
        <population>The analyses included only subjects who received fourth dose of vaccine in year two</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm 1: Dosing Interval 0, 8, 16, and 54 Weeks</title>
            <description>Participants received 3 doses of PfSPZ Vaccine (9 x10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
          </group>
          <group group_id="O2">
            <title>Experimental Arm 2: Dosing Interval 0, 1, 4, and 42 Weeks</title>
            <description>Participants received 3 doses of PfSPZ Vaccine (9 x10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Comparator 3a: Dosing Interval 0, 8, 16, and 54 Weeks</title>
            <description>Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Comparator 3b: Dosing Interval 0, 1, 4, and 42 Weeks</title>
            <description>Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local and Systemic Adverse Events in Year Two</title>
          <description>Incidence of local and systemic adverse events (AEs) graded by severity occurring within 7 days after vaccine administration during year two (booster dose)</description>
          <population>The analyses included only subjects who received fourth dose of vaccine in year two</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the primary endpoint, other (non-serious) adverse events were monitored 7 days from time of each vaccination during year one and year two. Deaths and serious AEs were monitored up to 21 months (duration of the study).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental Arm 1: Dosing Interval 0, 8, 16, and 54 Weeks</title>
          <description>Participants received 3 doses of PfSPZ Vaccine (9 x10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
        <group group_id="E2">
          <title>Experimental Arm 2: Dosing Interval 0, 1, 4, and 42 Weeks</title>
          <description>Participants received 3 doses of PfSPZ Vaccine (9 x10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
        <group group_id="E3">
          <title>Placebo Comparator 3a: Dosing Interval 0, 8, 16, and 54 Weeks</title>
          <description>Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Comparator 3b: Dosing Interval 0, 1, 4, and 42 Weeks</title>
          <description>Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>GRANULOCYTE COUNT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="69"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="70"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>NIAID cannot contact the FDA regarding the trial independent of the IND Sponsor (Sanaria, Inc.).&#xD;
Dr. Patrick Duffy is employed by the clinical sponsor, NIAID (clinical sponsor). Dr. Diawara is not employed by either sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Patrick Duffy</name_or_title>
      <organization>NIAID/LMIV</organization>
      <phone>301-761-5089</phone>
      <email>patrick.duffy@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

